Clinical Trial Detail

NCT ID NCT03502785
Title INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Inovio Pharmaceuticals
Indications

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

urethra transitional cell carcinoma

Therapies

Atezolizumab + INO-5401 + INO-9012

Age Groups: adult senior

No variant requirements are available.